Physician profile
Robert J Basak
NPI 1528258761
$1,962.52
in general payments reported to CMS, 2019-2025
27 companies · $15.06 in 2025
The $15.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $382 · 2021: $289 · 2022: $284 · 2023: $281 · 2024: $362 · 2025: $15.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.84 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $206.87 | 2019-2024 | Trelegy Ellipta |
| Abbvie INC. | $177.46 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $131.42 | 2020-2021 | |
| Genzyme Corporation | $117.00 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $109.55 | 2019-2024 | Breztri |
| Pfizer INC. | $76.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.04 | 2021-2022 | |
| Allergan, INC. | $65.16 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $60.74 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $59.97 | 2023 | Quviviq |
| Exact Sciences Corporation | $43.59 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.21 | 2019 | |
| Shire North American Group INC | $39.18 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.41 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.05 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $30.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.82 | 2019 | |
| Dexcom, INC. | $22.81 | 2023 | Dexcom G6 Transmitter |
| Vertical Pharmaceuticals, LLC | $21.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.08 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.67 | 2024 | Caplyta |
| Inari Medical, INC. | $18.25 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Amgen INC. | $17.69 | 2019 | |
| Abbott Laboratories | $14.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.72 | 2021 | |
| Circassia INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Basak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.